SG11201809973YA - Hot melt extrusion composition using direct compressible excipient as plasticizer - Google Patents
Hot melt extrusion composition using direct compressible excipient as plasticizerInfo
- Publication number
- SG11201809973YA SG11201809973YA SG11201809973YA SG11201809973YA SG11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- plasticizer
- melt extrusion
- darmstadt
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/05—Alcohols; Metal alcoholates
- C08K5/053—Polyhydroxylic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
- C08K5/0016—Plasticisers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L29/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
- C08L29/02—Homopolymers or copolymers of unsaturated alcohols
- C08L29/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Extrusion Moulding Of Plastics Or The Like (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16169693 | 2016-05-13 | ||
PCT/EP2017/061126 WO2017194576A1 (en) | 2016-05-13 | 2017-05-10 | Hot melt extrusion composition using direct compressible excipient as plasticizer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809973YA true SG11201809973YA (en) | 2018-12-28 |
Family
ID=56134085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809973YA SG11201809973YA (en) | 2016-05-13 | 2017-05-10 | Hot melt extrusion composition using direct compressible excipient as plasticizer |
Country Status (12)
Country | Link |
---|---|
US (1) | US11510986B2 (ko) |
EP (1) | EP3454836A1 (ko) |
JP (1) | JP6955517B2 (ko) |
KR (1) | KR102358069B1 (ko) |
CN (1) | CN109152739B (ko) |
BR (1) | BR112018071673B1 (ko) |
CA (1) | CA3023800A1 (ko) |
IL (1) | IL262908B (ko) |
MX (1) | MX2018012999A (ko) |
PH (1) | PH12018502055A1 (ko) |
SG (1) | SG11201809973YA (ko) |
WO (1) | WO2017194576A1 (ko) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2542346B2 (ja) | 1987-05-30 | 1996-10-09 | 日本合成化学工業株式会社 | 高重合度ポリビニルアルコ−ルの製造法 |
JP2577698B2 (ja) * | 1993-08-05 | 1997-02-05 | 信道 中野 | 流動性の高いソルビトール粉末の製造方法 |
DE19617487A1 (de) * | 1996-05-02 | 1997-11-06 | Merck Patent Gmbh | Geschmacksverbesserung von Arzneimittelwirkstoffen |
JP4783278B2 (ja) * | 2003-02-03 | 2011-09-28 | ノバルティス アーゲー | 医薬製剤 |
US20080311240A1 (en) * | 2004-06-17 | 2008-12-18 | Cargill Incorporated | Steam Agglomeration of Polyols |
BRPI0714963A2 (pt) * | 2006-08-16 | 2013-07-30 | Novartis Ag | processo de fabricaÇço de dispersÕes sàlidas de compostos terapÊuticos altamente cristalinos |
ES2720626T3 (es) * | 2008-06-20 | 2019-07-23 | Merck Patent Gmbh | Combinación de poliol compresible directamente |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
ES2655719T3 (es) * | 2009-07-10 | 2018-02-21 | Merck Patent Gmbh | Sustancia auxiliar con bajo contenido de agua para formación de comprimidos y procedimiento para su fabricación |
US8551529B2 (en) * | 2009-07-10 | 2013-10-08 | Merck Patent Gmbh | Composition for the production of tablets, and method for the production of said composition |
GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
CN102204868B (zh) * | 2011-05-18 | 2014-01-22 | 北京化工大学 | 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺 |
RU2013155713A (ru) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
US20130071476A1 (en) * | 2011-08-19 | 2013-03-21 | Subraman Rao Cherukuri | Rapid Melt Controlled Release Taste-Masked Compositions |
CN105012242A (zh) * | 2015-07-21 | 2015-11-04 | 南京中医药大学 | 一种厚朴酚或和厚朴酚或两者混合物固体分散体及其热熔挤出制备方法 |
-
2017
- 2017-05-10 KR KR1020187036153A patent/KR102358069B1/ko active IP Right Grant
- 2017-05-10 MX MX2018012999A patent/MX2018012999A/es unknown
- 2017-05-10 WO PCT/EP2017/061126 patent/WO2017194576A1/en unknown
- 2017-05-10 JP JP2018559698A patent/JP6955517B2/ja active Active
- 2017-05-10 EP EP17721419.4A patent/EP3454836A1/en active Pending
- 2017-05-10 US US16/301,327 patent/US11510986B2/en active Active
- 2017-05-10 SG SG11201809973YA patent/SG11201809973YA/en unknown
- 2017-05-10 CN CN201780029468.5A patent/CN109152739B/zh active Active
- 2017-05-10 BR BR112018071673-1A patent/BR112018071673B1/pt active IP Right Grant
- 2017-05-10 CA CA3023800A patent/CA3023800A1/en active Pending
-
2018
- 2018-09-25 PH PH12018502055A patent/PH12018502055A1/en unknown
- 2018-11-11 IL IL262908A patent/IL262908B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12018502055A1 (en) | 2019-06-24 |
BR112018071673A2 (pt) | 2019-02-19 |
WO2017194576A1 (en) | 2017-11-16 |
IL262908A (en) | 2018-12-31 |
US11510986B2 (en) | 2022-11-29 |
CN109152739B (zh) | 2022-09-30 |
IL262908B (en) | 2022-04-01 |
US20200254098A1 (en) | 2020-08-13 |
KR20190008556A (ko) | 2019-01-24 |
BR112018071673B1 (pt) | 2024-02-27 |
KR102358069B1 (ko) | 2022-02-03 |
JP2019515006A (ja) | 2019-06-06 |
EP3454836A1 (en) | 2019-03-20 |
CN109152739A (zh) | 2019-01-04 |
JP6955517B2 (ja) | 2021-10-27 |
MX2018012999A (es) | 2019-01-28 |
CA3023800A1 (en) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11202000494UA (en) | Drug delivery composition | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201809970UA (en) | Use of amino sugar as plasticizer | |
SG11201909906QA (en) | Organic compounds | |
SG11201909059XA (en) | Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol | |
SG11201910043PA (en) | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |